Premium
Double‐blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.
Author(s) -
Butler RC,
Goddard DH,
Higgens CS,
Hollingworth P.,
Pease CT,
Stodell MA,
Scott JT
Publication year - 1985
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1985.tb05110.x
Subject(s) - phenylbutazone , flurbiprofen , medicine , gout , arthritis , double blind , gouty arthritis , gastroenterology , anesthesia , pharmacology , placebo , pathology , alternative medicine
Flurbiprofen has been compared with phenylbutazone in a double‐blind study involving 33 patients with acute gout. Patients received either flurbiprofen 400 mg daily for 48 h followed by 200 mg daily, or phenylbutazone 800 mg daily for 48 h followed by 400 mg daily. The drugs were of comparable efficacy, while side‐effects were uncommon and relatively mild. Flurbiprofen appears to be a satisfactory alternative to phenylbutazone in the management of acute gouty arthritis.